Faced with many barriers and less able to maintain social and physical distance, persons with disabilities are at greater risk of contracting COVID-19 and falling severely ill as a result of the disease. However, in the EU they have not been explicitly included in priority groups for vaccination. National vaccination strategies do not have clear-cut […]
Read More
Commission strengthens transparency and authorisation mechanism for exports of COVID-19 vaccines
The European Commission has introduced the principles of reciprocity and proportionality as new criteria to be considered for authorising exports under the transparency and authorisation mechanism for COVID-19 vaccine exports. This system has significantly improved the transparency of exports. Nevertheless, the objective to ensure timely access to COVID-19 vaccines for EU citizens is still not […]
Read More
COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events
EMA is aware that the Danish Health Authority has paused its vaccination campaign with COVID-19 Vaccine AstraZeneca. This was decided as a precautionary measure while a full investigation is ongoing into reports of blood clots in people who received the vaccine, including one case in Denmark where a person died. Some other Member States have […]
Read More
European Commission authorises fourth vaccine against COVID-19: Janssen
The European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the fourth COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and […]
Read More
EU urges AstraZeneca to explain vaccine delivery delays
▶️ Watch the press conference by Commissioner @SKyriakidesEU on vaccine deliveries and on the export transparency scheme. #StrongerTogether https://t.co/iczvKiAiRm — European Commission 🇪🇺 (@EU_Commission) January 25, 2021 Last Friday, the company AstraZeneca surprisingly informed the Commission and the European Union Member States that it intends to supply considerably fewer doses in the coming weeks than […]
Read More
Commission concludes exploratory talks with Valneva to secure a new potential vaccine
The European Commission concluded exploratory talks with the pharmaceutical company Valneva with a view to purchasing its potential vaccine against COVID-19. The envisaged contract with Valneva would provide for the possibility for all EU Member States to purchase together 30 million doses, and they could further purchase up to 30 million more doses. This finalisation […]
Read More
EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 vaccine developed by AstraZeneca and Oxford University. The assessment of the vaccine, known as COVID-19 Vaccine AstraZeneca, will proceed under an accelerated timeline. An opinion on the marketing authorisation could be issued by 29 January during the meeting of EMA’s scientific committee for human […]
Read More
European Commission authorises second safe and effective vaccine against COVID-19
The European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by Moderna, the second COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed […]
Read More
Affordable, accessible and safe medicines for all: the Commission presents a Pharmaceutical Strategy for Europe
The Commission has adopted a Pharmaceutical Strategy for Europe to ensure patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity and sustainability of the EU’s pharmaceutical industry. Europe’s Pharmaceutical Strategy has four main objectives: Ensuring access to affordable medicines for patients, and addressing unmet medical needs (e.g. in the […]
Read More